Thursday, April 17, 2025 11:25 PM EDT
Loading number of views...
Image Source: Pixabay
Fresh food prices eased, yet inflationary pressures broadened in March
Consumer inflation in Japan edged down to 3.6% year on year in March (vs 3.7% in February and market consensus) as fresh food prices stabilized modestly. Yet core inflation, excluding fresh food, accelerated to 3.2% (vs 3.0% in February) and core-core inflation, excluding fresh food and energy, also accelerated to a 2.9% pace (vs 2.6% in February). Both were in line with market consensus.
On a monthly basis, inflation rebounded 0.3% month on month, seasonally adjusted, in March (vs -0.1% in February) with both goods and services rising 0.2% each. Fresh food prices declined for a second month, yet the earlier pickup in costs is now passing on to other manufactured food prices and services, such as eating out.
April Tokyo CPI inflation data will be released on Friday. Prices are set to accelerate even faster than in March. This will also complicate the BoJ’s rate decision in the near term as trade war risks increase.
Core inflation picked up in March
Source: CEIC
BoJ watch
Downside risks to GDP are growing significantly even as inflation is accelerating. Also, Japanese yen trends are being closely watched by the US administration. We dropped our long-held May rate hike call last week, pushing it to July. We expect the BoJ to keep its policy rate unchanged at its May meeting even though inflation is still the key concern. The BoJ is likely to focus on economic uncertainty for now, just like many other central banks. The BoJ will base rate decisions on what happens with concessions made between the US and Japan and where the US tariffs policies go from here. We believe that by July, things will be clearer. Trade concessions will likely take shape by then, giving the BoJ more confidence to raise its policy rate in July. The BoJ's rate hike pace will be quite gradual. For now, we still pencil in two hikes next year -- in April and October 2026.
More By This Author:
US Drug Prices And Shortages Set To Rise Despite Trump’s Latest Executive Order FX Daily: Forget The Old Central Bank Currency Link Bank Of Korea’s Rate Cut Pause Probably Won’t Last Long
Disclaimer: This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. (“ING”) solely for information purposes without regard to any ...
more
Disclaimer: This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. (“ING”) solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. ING forms part of ING Group (being for this purpose ING Group NV and its subsidiary and affiliated companies). The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.
The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.
Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is deemed authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. The nature and extent of consumer protections may differ from those for firms based in the UK. Details of the Temporary Permissions Regime, which allows EEA-based firms to operate in the UK for a limited period while seeking full authorisation, are available on the Financial Conduct Authority’s website.. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.
less
How did you like this article? Let us know so we can better customize your reading experience.
